Platelet-delivered factor VIII provides limited resistance to anti-factor VIII inhibitors

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 7, 2008, Pages 1160-1166

  Gewirtz, J ^a   Thornton, M A ^b   Rauova, L ^a   Poncz, Mortimer ^a,c  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b FLORIDA A AND M UNIVERSITY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Factor VIII; Gene therapy; Hemophilia A; Inhibitors; Platelet

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; FERRIC CHLORIDE; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ACUTE DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; CHRONIC DISEASE; CONTROLLED STUDY; GENE DELIVERY SYSTEM; GENE THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ANIMALS; ANTIBODIES; BLOOD PLATELETS; CAROTID ARTERY DISEASES; DISEASE MODELS, ANIMAL; FACTOR VIII; GENE THERAPY; IMMUNE TOLERANCE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC;

EID: 45549109031     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.02992.x     Document Type: Article

References (30)

1. Castaldo G, D'Argenio V, Nardiello P, Zarrilli F, Sanna V, Rocino A, Coppola A, Di Minno G, Salvatore F. Haemophilia A: Molecular insights. Clin Chem Lab Med 2007; 45: 450-61.
2. Ponder KP. Gene therapy for hemophilia. Curr Opin Hematol 2006; 13: 301-7.
3. Yarovoi H, Kufrin D, Eslin DE, Zhu H, Wilcox DA, Camire R, Fakharzadeh SS, Kowalska MA, Montgomery RR, Poncz M. Factor VIII ectopically expressed in platelets. Efficacy in hemophilia A treatment. Blood 2003; 102: 4006-13.
4. Yarovoi H, Nurden AT, Montgomery RR, Nurden P, Poncz M. Intracellular interaction of Von Willebrand Factor and Factor VIII depends on cellular context: Lessons from platelet expressed Factor VIII. Blood 2005; 105: 4674-6.
5. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 1995; 10: 119-21.
6. Shi Q, Wilcox DA, Fahs SA, Weiler H, Wells CW, Cooley BC, Desai D, Morateck PA, Gorski J, Montgomery RR. Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies. J Clin Invest 2006; 116: 1974-82.
7. High KA. The leak stops here: Platelets as delivery vehicles for coagulation factors. J Clin Invest 2006; 116: 1840-2.
8. Andrews N. Putting platelets to work to circumvent hemophilia inhibitors. Hematologist 2006; 3: 8.
9. Dasgupta S, Navarrete AM, Delignat S, Wootla B, Andre S, Nagaraja V, Lacroix-Desmazes S, Kaveri SV. Immune response against therapeutic factor VIII in hemophilia A patients - a survey of probable risk factors. Immunol Lett 2007; 110: 23-8.
10. Mathew P. Current opinion on inhibitor treatment options. Semin Hematol 2006; 43: S8-13.
11. Fay WP, Parker AC, Ansari MN, Zheng X, Ginsburg D. Vitronectin inhibits the thrombotic response to arterial injury in mice. Blood 1999; 93: 1825-30.
12. Pittman DD, Alderman EM, Tomkinson KN, Wang JH, Giles AR, Kaufman RJ. Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII. Blood 1993; 81: 2925-35.
13. Hashimoto Y, Ware J. Identification of essential GATA and Ets binding motifs within the promoter of the platelet glycoprotein Ib alpha gene. J Biol Chem 1995; 270: 24532-9.
14. Fujita H, Hashimoto Y, Russell S, Zieger B, Ware J. In vivo expression of murine platelet glycoprotein Ibalpha. Blood 1998; 92: 488-95.
15. Scandella D, Gilbert GE, Shima M, Nakai H, Eagleson C, Felch M, Prescott R, Rajalakshmi KJ, Hoyer LW, Saenko E. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood 1995; 86: 1811-9.
16. Villard S, Piquer D, Raut S, Leonetti JP, Saint-Remy JM, Granier C. Low molecular weight peptides restore the procoagulant activity of factor VIII in the presence of the potent inhibitor antibody ESH8. J Biol Chem 2002; 277: 27232-9.
17. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor IIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
18. Saenko EL, Shima M, Gilbert GE, Scandella D. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition. J Biol Chem 1996; 271: 27424-31.
19. Saenko EL, Shima M, Rajalakshmi KJ, Scandella D. A role for the C2 domain of factor VIII in binding to von Willebrand factor. J Biol Chem 1994; 269: 11601-5.
20. Hsu TC, Pratt KP, Thompson AR. The factor VIII C1 domain contributes to platelet binding. Blood 2008; 111: 200-8.
21. Handagama P, Rappolee DA, Werb Z, Levin J, Bainton DF. Platelet alpha-granule fibrinogen, albumin, and immunoglobulin G are not synthesized by rat and mouse megakaryocytes. J Clin Invest 1990; 86: 1364-8.
22. George JN, Saucerman S, Levine SP, Knieriem LK, Bainton DF. Immunoglobulin G is a platelet alpha granule-secreted protein. J Clin Invest 1985; 76: 2020-5.
23. Millward TA, Heitzmann M, Bill K, Langle U, Schumacher P, Forrer K. Effect of constant and variable domain glycosylation on pharmacokinetics of therapeutic antibodies in mice. Biologicals 2008; 36: 41-7.
24. Kufrin D, Eslin DE, Bdeir K, Murciano J-C, Kuo A, Kowalska MA, Degen JL, Sachais BS, Cines DB, Poncz M. Anti-thrombotic thrombocytes. Ectopic expression of urokinase-type plasminogen activator in platelets. Blood 2003; 102: 926-33.
25. Mordenti J, Osaka G, Garcia K, Thomsen K, Licko V, Meng G. Pharmacokinetics and interspecies scaling of recombinant human factor VIII. Toxicol Appl Pharmacol 1996; 136: 75-8.
26. Shi Q, Fahs SA, Wilcox DA, Kuether EL, Weiler H, Montgomery RR. In the presence of pre-existing factor VIII (FVIII) immunity, hematopoietic stem cells (HSC) that are genetically modified to express FVIII in platelets were successfully transplanted into hemophilic mice under myeloablative and various non-myeloablative conditions. Blood 2007; 110: 236a.
27. Italiano J, Richardson JL, Folkman J, Klement G. Blood platelets organize pro- and anti-angiogenic factors into separate, distinct alpha granules: Implications for the regulation of angiogenesis. Blood 2006; 108: 120a.
28. Olson PS, Ljungqvist U, Bergentz SE. Analysis of platelet, red cell and fibrin content in experimental arterial and venous thrombi. Thromb Res 1974; 5: 1-19.
29. Furie BC, Furie B. Tissue factor pathway vs. collagen pathway for in vivo platelet activation. Blood Cells Mol Dis 2006; 36: 135-8.
30. Spira J, Plyushch OP, Andreeva TA, Andreev Y. Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes. Blood 2006; 108: 3668-73.